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Fetal interventions in the setting of the coronavirus
disease 2019 pandemic: statement from the North
American Fetal Therapy Network
Being healthcare providers (HCPs) for pregnant women
and their fetuses, we have been challenged to balance the
risks and benefits of care provision, as we adapt our estab-
lished practice in the setting of the coronavirus disease
(COVID-19; severe acute respiratory syndrome coronavirus
2 [SARS-CoV-2] infection) pandemic.1,2 The risks include
the interventional risk to the fetus and mother, treatment-
related SARS-CoV-2 exposure to the HCP, the effect on
maternal and fetal health because of procedures done in the
setting of maternal SARS-CoV-2 infection, and the risks of
not intervening in a timely manner on fetal and/or neonatal
outcome.1
In an effort to balance these risks and to continue
providing evidence-based fetal interventions that reduce fetal
morbidity and mortality, the North American Fetal Therapy
Network (NAFTNet, https://www.naftnet.org) suggests the
following approach to fetal interventions in the setting of the
COVID-19 pandemica: prenatal care should be adjusted by
optimizing appointment intervals; patient self-assessment,
such as home blood pressure monitoring; and the use of
virtual consultations.2,3 The gestational ageedependent na-
ture of reproductive choice and the availability of effective
interventions that can reduce fetal and neonatal morbidity
and mortality make prenatal diagnosis and most established
fetal therapies time sensitive, the delay of which may worsen
perinatal outcome.4 These procedures should therefore not be
defined as “elective,” and their provision should be guided by
local institutional policies and practices in the context of
resource availability.
The North American Fetal Therapy Network suggests the
following specific considerations related to fetal interventions:
1. Because of the life-threatening, morbidity-related, and/or
time-sensitive nature of conditions requiring interven-
tion, most fetal procedures are not “elective.” These
include, but are not limited to:
a. Fetal blood transfusions
b. Interventions for complicated monochorionic mul-
tiple gestations, including fetoscopic placental laser
surgery or selective reduction
c. Shunting procedures for conditions with substantial
fetal compromise, such as hydropic hydrothoraces or
cystic lung lesions
d. Open fetal surgical procedures that are not experi-
mental or under research protocols, such as, but not
limited to, open maternal-fetal surgery for fetal
myelomeningocele repair and ex utero intrapartum
therapy for anticipated neonatal airway compromise
2. The above recommendations should be applied
regardless of a patient’s COVID-19 status. The decision
to intervene may be influenced by the maternal condi-
tion. Maternal health always takes priority over fetal
status.
3. The limited evidence to date regarding the risk of vertical
transmission of SARS-CoV-2 infection through fetal
intervention should be included in the informed consent
discussion before such procedures.
4. Fetal therapists should strive to avoid transplacental
passage of their needle or (in particular) fetoscope or
shunt trocar. Avoiding transplacental procedures be-
comes especially pertinent when there is a potential risk
of maternal-fetal viral transmission. An exception might
be fetal transfusion into an anterior placental cord
insertion, if the fetal intrahepatic vein was inaccessible.
Open fetal surgical procedures may carry a higher risk of
such transmission.
5. General anesthesia is a high-risk procedure for viral
transmission. The anesthetic risks, and that of horizontal
transmission of SARS-CoV-2 infection to HCPs, should
be discussed among the patient and her HCPs.5 Pro-
cedures that violate the aerodigestive mucosa and/or
result in body fluid aerosolization are associated with
SARS-CoV-2 transmission.5 Most fetal procedures can be
performed under conscious sedation and local anes-
thesia, which reduces maternal risk and SARS-CoV-2
exposure risk to HCPs.
6. Appropriate personal protective equipment (PPE) must
be worn for all encounters with patients diagnosed as
having COVID-19 or patients classified as person under
investigation (PUI). This applies for any potentially
aerosolizing procedures, including endotracheal intuba-
tion for general anesthesia or neonatal intubation.2,5
7. Equipment, including ultrasound machines, must be
cleansed thoroughly between patients, especially if the
patient is positive for COVID-19, following stringent
cleansing protocols.6
8. Only essential HCPs should participate in procedures on
patients with positive COVID-19 or patients classified as
PUI.
9. All nonessential personnel should limit direct patient
contact. Whenever possible, patient encounters, for
example, subspecialty consultation or result follow-up,
should be conducted virtually.3 Dedicated fetal therapy
nursing and care coordination remain critical compo-
nents of the fetal care team.
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10. The potential exacerbation of known or unrecognized
maternal SARS-CoV-2 infection that could result in
increased fetal or maternal morbidity or mortality with
any intervention must be considered. Where appropriate,
infectious disease consultation should be entertained.
11. Decisions should be made based on local medical,
operational, and organizational considerations, influ-
enced by local COVID-19 burden. Parents should be
informed that treatment availability may change at short
notice, because of local healthcare adjustments as they
adapt to evolving pandemic trends.
12. Preoperative SARS-CoV-2 testing for patients undergo-
ing fetal interventions should follow local policies and
guidelines, according to access to testing and result
response time. For patients who receive positive test re-
sults for SARS-CoV-2 or are symptomatic, procedures
should be delayed for 14 days or until patients meet local
criteria for disease resolution. If the fetal condition re-
quires immediate intervention, and if the mother is
stable, the procedure should be performed using
appropriate PPE.
13. Practice guidelines for procedures during the COVID-19
pandemic are continually evolving as information
emerges. The North American Fetal Therapy Network
will closely monitor emerging evidence and will update
their guidelines accordingly (https://www.naftnet.org).
14. All interventional research protocols should be sus-
pended during the pandemic. No clinical benefit for the
fetus or newborn is lost, because the experimental out-
comes are unknown. However, we encourage recruit-
ment of pregnant women and neonates with SARS-CoV-
2 infection into registries that may clarify the risk of
vertical transmission (Table).
15. Fetal therapy centers must carefully consider whether
they can still offer certain, highly resource-intensive, fetal
procedures if their staffing becomes depleted, because of
either illness or deployment to other intensive care areas.
In regions with multiple fetal therapy programs, this may
be a time for collaboration, volume reduction, and/or
referral of certain cases.
16. Patients traveling between states, provinces, or countries
should be counseled that, by such travel, they may expose
themselves to a higher risk of SARS-CoV-2 infection.
They may also become obliged to remain at their
destined center for an unpredictable time period. After
some procedures, patients may return earlier than usual
TABLE




PRIORITY https://priority.ucsf.edu/ United States only Pregnant or recently pregnant women, either
under investigation for SARS-CoV-2 infection or
with confirmed COVID-19
COVI-Preg https://www.covi-preg.ch International Any pregnant patient suspected of
SARS-CoV-2 infection
PAN COVID https://pan-covid.org International Any woman in pregnancy or postnatal period and/






All women with SARS-CoV-2 infection in
pregnancy or within 6 wk after delivery, at any
MFMU hospital site
CHOPAN https://www.covid19chopan.health Australia, New Zealand,
and Pacific region
All women diagnosed as having COVID-19 in
pregnancy. Neonatal outcomes to 1 mo of age
UKOSS https://www.npeu.ox.ac.uk/ukoss/current-
surveillance/covid-19-in-pregnancy
United Kingdom only Incidence of hospitalization with SARS-CoV-2
infection in pregnancy, assessing maternal and
infant outcomes
ROI COVID-19 https://www.ucc.ie/en/npec/roicovid-19study/ Ireland only All pregnant women and newborns aged <29
d who have been tested for SARS-CoV-2
NethOSS https://www.nvog.nl/actueel/registratie-van-
covid-19-positieve-zwangeren-in-nethoss/
Netherlands only Pregnant women with SARS-CoV-2 infection
CAN COVID-
Preg
https://ridprogram.med.ubc.ca/cancovid-preg/ Canada only Pregnant women with COVID-19 infection and
their newborns up to 6 weeks
CAN COVID-Preg, Canadian COVID-19 in Pregnancy Surveillance; CHOPAN, Coronavirus Health Outcomes in Pregnancy and Neonates; COVID-19, coronavirus disease 2019; COVI-Preg, In-
ternational COVID-19 and Pregnancy Registry; MFMU, Maternal-Fetal Medicine Units; NethOSS, Netherlands Obstetric Surveillance System; PAN COVID, Pregnancy and Neonatal outcomes for
women with COVID-19; PRIORITY, Pregnancy Coronavirus Outcomes Registry; ROI COVID-19, Republic of Ireland, COVID-19; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2;
UKOSS, UK Obstetric Surveillance System.
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to their referring HCPs for ongoing monitoring and care.
Fetal therapy centers should remain engaged with the
referring HCP by phone or telemedicine. If travel re-
strictions are implemented, patients who need to travel
to a distant fetal therapy center may require supporting
documentation. Some centers may decline to accept
patients with a positive result for COVID-19 testing or
come from regions with a high infection prevalence.
The North American Fetal Therapy Network’s suggested
approach to the fetus, in the setting of the COVID-19
pandemic, emphasizes the need for a comprehensive multi-
disciplinary approach to maternalefetal care. We must
carefully weigh the risks and benefits of all fetal interventions,
considering whether the potential benefits may or may not be
achieved with alternate or delayed therapeutic approaches.
The risks of exposure of HCPs to SARS-CoV-2 and the
availability of local resources must be considered in such
decisions. During the COVID-19 pandemic, fetal in-
terventions should not simply be defined as “elective”
procedures. -
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aEvidence-based guidance for the provision of antenatal care, prenatal
diagnosis, fetal therapy, and intra- and postpartum care and the optimal
approach to the surgical patient in the setting of the COVID-19 pandemic
is rapidly evolving. Recommendations must be adapted considering local
SARS-CoV-2 infection prevalence and resource availability. The North
American Fetal Therapy Network recommends ongoing consultation with
reputable organizations and institutions, such as the Centers for Disease
Control and Prevention, American College of Obstetricians and
Gynecologists, International Society for Ultrasound in Obstetrics and
Gynecology, American Institute of Ultrasound in Medicine, Society of
Obstetricians and Gynaecologists of Canada, International Fetal Medicine
and Surgery Society, International Society for Prenatal Diagnosis, and
Society for Maternal-Fetal Medicine, for up-to-date information regarding
specific pregnancy care in the setting of the COVID-19 pandemic.
Operating room policies and procedures should follow local guidelines in
addition to those developed by surgical and anesthetic societies,
including the American College of Surgeons, Association of Operating
Room Nurses, Society for Obstetric Anesthesia and Perinatology,
Canadian Association of Paediatric Surgeons, and Society of American
Gastrointestinal and Endoscopic Surgeons.
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This communication has been published in the middle of the coronavirus
disease 2019 pandemic and is available via expedited publication to assist
patients and healthcare providers.
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Screening all pregnant women admitted to labor and
delivery for the virus responsible for coronavirus
disease 2019
OBJECTIVE: The coronavirus disease 2019 (COVID-19)
pandemic sharply escalated in the United States in March and
April of 2020. General medical and obstetrical guidelines for
managing suspected or confirmed COVID-19 cases mostly
rely on maternal symptoms or close proximity to positive
contacts to trigger testing and subsequently diagnose
COVID-19.1 However, it has become apparent that most
cases of COVID-19 are the result of viral dissemination
from asymptomatic individuals.2 Persons who may
unknowingly spread COVID-19 are often young and
healthy, which fits the demographic of many obstetrical
patients. Because medical staff have been urged to conserve
limited personal protective equipment (PPE) for suspected
or confirmed cases,3 the risk of COVID-19 transmission to
frontline healthcare workers from asymptomatic carriers
has increased. Similarly, the risk of COVID-19
transmission from mother to her infant or to other
obstetrical patients on a shared antepartum or postpartum
unit has also increased. Therefore, we proposed that
routine testing for COVID-19 should be performed in all
obstetrical patients admitted to labor and delivery (L&D)
unit, regardless of maternal symptomatology, allowing for
appropriate triage, adequate obstetrical and neonatal
management, and safe patient transport within
overcrowded hospitals.
At the time of this writing, COVID-19 testing has been
recommended only for patients presenting with symptoms
and those in close proximity to laboratory-confirmed positive
patients.4 The Society for Maternal-Fetal Medicine in
conjunction with the Centers for Disease Control and Pre-
vention (CDC) have advised not to prioritize testing of
asymptomatic patients.5 This may lead to unrecognized viral
transmission and incorrect use of PPE.
The primary objective of this study was to determine the
accuracy of maternal symptomatology in predicting COVID-
19 as confirmed by rapid laboratory testing. Secondary ob-
jectives were the rate of neonatal COVID-19 and the effect of
routine maternal testing on the use of PPE compared with its
use based on symptom-driven testing.
STUDY DESIGN: This was a retrospective cohort study of all
obstetrical patients admitted to L&D from March 30, to April
12, 2020. Routine COVID-19 testing was implemented
during this time period. Testing was performed in all
admitted patients, regardless of indication for admission or
presence of symptoms. Institutional review board approval
was obtained in addition to approval by a COVID-
19especific research committee within our institution. The
study was performed at the NYU Winthrop Hospital of the
NYU Langone Health System; our hospital performs
approximately 4800 deliveries per year.
All women were asked about symptoms (fever, cough,
shortness of breath). The presence of 1 or more of the
aforementioned symptoms was used to determine whether
the patient was symptomatic. Sampling was performed by a
resident physician or a physician assistant in appropriate
PPE using a nasal swab in a negative-pressure room with
closed doors. Each nasopharyngeal swab was collected in
the GeneXpert Nasopharyngeal Sample Collection Kit for
Viruses (Cepheid, Sunnyvale, CA) and transferred to the
laboratory. Within the negative-pressure fume hood, 30 mL
of viral culture media from the collection kit was trans-
ferred into the Xpert Xpress SARS-CoV-2 cartridge
(Cepheid, Sunnyvale, CA). The cartridge was subsequently
placed in Cepheid’s equipment for polymerase chain re-
action (Cepheid, Sunnyvale, CA).6 Polymerase chain
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